Therapeutic management of atypical antipsychotic‑related metabolic dysfunctions using GLP‑1 receptor agonists: A systematic review

Vasiliu,Octavian

doi:10.3892/etm.2023.12054

Therapeutic management of atypical antipsychotic‑related metabolic dysfunctions using GLP‑1 receptor agonists: A systematic review

Authors:
- Octavian Vasiliu
View Affiliations

Affiliations: Department of Psychiatry, 'Dr. Carol Davila' University Emergency Central Military Hospital, 010816 Bucharest, Romania
Published online on: June 1, 2023 https://doi.org/10.3892/etm.2023.12054
Article Number: 355
Copyright: © Vasiliu . This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Metabolic disorders (MDs) like obesity, dyslipidemia, and type 2 diabetes are more frequently observed in patients diagnosed with psychiatric disorders undergoing treatment with antipsychotics, particularly atypical agents, than in the general population. The second generation of antidiabetics (SGAD) has been associated with cardiovascular benefits in large clinical trials which represent an important advantage over first‑generation agents and might be of interest in the psychiatric population where multiple risk factors for cardiovascular disease (e.g., smoking, lack of exercise, and lack of healthy diet) are common occurrences. Therefore, this systematic review focused on the evaluation of the glucagon‑like peptide‑1 receptor agonists (GLP1‑RAs), as a representative of the SGAD, to determine whether these agents may be recommended in patients with psychiatric disorders and MDs. For analysis, three electronic databases and clinical trial registers were explored for papers published between January 2000 and November 2022. After applying the inclusion and exclusion criteria, 20 clinical and preclinical trials, therapeutic guidelines, and meta‑analyses were reviewed, and clinical recommendations were formulated. The large majority of the reviewed data (nine papers) were graded 'moderate' based on the GRADE criteria. The efficacy and tolerability of liraglutide and exenatide in the management of antipsychotic‑induced MDs were supported by evidence of average quality, while the results regarding other GLP‑1RAs were not sufficient to formulate a recommendation for their administration in this specific population. Clozapine and olanzapine had the most negative consequences on body weight, glycemic, and lipid metabolism. Therefore, careful monitoring of metabolic parameters is required when these are prescribed. Liraglutide and exenatide may be recommended as augmentative agents to metformin therapy, especially in patients receiving these two atypical antipsychotics, but most of the reviewed data supported the efficacy of GLP‑1RAs only during the treatment administration. The two follow‑up studies retrieved in the literature reported modest effects after GLP‑1RA discontinuation after 1 year; therefore, long‑term monitoring of metabolic parameters is required. More research is needed, and three randomized clinical trials are already ongoing, to evaluate the effects of GLP‑1RAs in decreasing body weight, but also on other important metabolic variables, such as HbA1c status, fasting glucose levels, and lipid levels in patients receiving antipsychotic treatment.

View Figures

View References

1	Cernea S, Dima L, Correll CU and Manu P: Pharmacological management of glucose dysregulation in patients treated with second-generation antipsychotics. Drugs. 80:1763–1781. 2020.PubMed/NCBI View Article : Google Scholar
2	Chang CK, Hayes RD, Perera G, Broadbent MT, Fernandes AC, Lee WE, Hotopf M and Stewart R: Life expectancy at birth for people with serious mental illness and other major disorders from a secondary mental health care case register in London. PLoS One. 6(e19590)2011.PubMed/NCBI View Article : Google Scholar
3	Kessing LV, Vradi E, McIntyre RS and Andersen PK: Causes of decreased life expectancy over the life span in bipolar disorder. J Affect Disord. 180:142–147. 2015.PubMed/NCBI View Article : Google Scholar
4	Dieset I, Andreassen OA and Haukvik UK: Somatic comorbidity in schizophrenia: Some possible biological mechanisms across the life span. Schizophr Bull. 42:1316–1319. 2016.PubMed/NCBI View Article : Google Scholar
5	Vasiliu O, Vasile D, Făinărea AF, Pătrașcu MC, Morariu EA, Manolache R, Alexandru I and Androne FT: Analysis of risk factors for antipsychotic-resistant schizophrenia in young patients-a retrospective analysis. Rom J Mil Med. (CXXI): 25–29. 2018.
6	Rajkumar AP, Horsdal HT, Wimberley T, Cohen D, Mors O, Børglum AD and Gasse C: Endogenous and antipsychotic-related risks for diabetes mellitus in young people with schizophrenia: A Danish population-based cohort study. Am J Psychiatry. 174:686–694. 2017.PubMed/NCBI View Article : Google Scholar
7	Vasiliu O: Therapeutic management of schizophrenia and substance use disorders dual diagnosis-clinical vignettes. Rom J Mil Med. 121:26–34. 2018.
8	Ebdrup BH, Knop FK, Ishøy PL, Rostrup E, Fagerlund B, Lublin H and Glenthøj B: Glucagon-like peptide-1 analogs against antipsychotic-induced weight gain: Potential physiological benefits. BMC Med. 10(92)2012.PubMed/NCBI View Article : Google Scholar
9	Kouidrat Y and Amad A: GLP-1 agonists for metabolic disorders in schizophrenia. Schizophr Res. 204:448–449. 2019.PubMed/NCBI View Article : Google Scholar
10	Vasiliu O: Esketamine for treatment-resistant depression: A review of clinical evidence (Review). Exper Ther Med. 25(111)2023.PubMed/NCBI View Article : Google Scholar
11	Hatziagelaki E, Tsiavou A, Gerasimou C, Vavougios GD, Spathis A, Laskos E, Papageorgiou C and Douzenis A: Effects of olanzapine on cytokine profile and brain-derived neurotrophic factor in drug-naïve subjects with first-episode psychosis. Exp Ther Med. 17:3071–3076. 2019.PubMed/NCBI View Article : Google Scholar
12	Ermakov EA, Melamund MM, Buneva VN and Ivanova SA: Immune system abnormalities in schizophrenia: An integrative view and translational perspectives. Front Psychiatry. 13(880568)2022.PubMed/NCBI View Article : Google Scholar
13	Mizuki Y, Sakamoto S, Okahisa Y, Yada Y, Hashimoto N, Takaki M and Yamada N: Mechanisms underlying the comorbidities of schizophrenia and type 2 diabetes mellitus. Int J Neuropsychopharmacol. 24:367–382. 2021.PubMed/NCBI View Article : Google Scholar
14	Libowitz MR and Nurmi EL: The burden of antipsychotic-induced weight gain and metabolic syndrome in children. Front Psychiatry. 12(623681)2021.PubMed/NCBI View Article : Google Scholar
15	Chen J, Huang XF, Shao R, Chen C and Deng C: Molecular mechanisms of antipsychotic drug-induced diabetes. Front Neurosci. 11(643)2017.PubMed/NCBI View Article : Google Scholar
16	Goh KK, Chen CYA, Wu TH, Chen CH and Lu ML: Crosstalk between schizophrenia and metabolic syndrome: The role of oxytocinergic dysfunction. Int J Mol Sci. 23(7092)2022.PubMed/NCBI View Article : Google Scholar
17	Carey ME, Barnett J, Doherty Y, Barnard K, Daly H, French P, Gossage-Worrall R, Hadjiconstantinou M, Hind D, Mitchell J, et al: Reducing weight gain in people with schizophrenia, schizoaffective disorder, and first episode psychosis: Describing the process of developing the Structured lifestyle Education for People with SchizophrEnia (STEPWISE) intervention. Pilot Feasibility Stud. 4(186)2018.PubMed/NCBI View Article : Google Scholar
18	Budisteanu M, Andrei E, Lica F, Hulea DS, Velicu AC, Mihailescu I, Riga S, Arghir A, Papuc SM, Sirbu CA, et al: Predictive factors in early onset schizophrenia. Exp Ther Med. 20(210)2020.PubMed/NCBI View Article : Google Scholar
19	Vasiliu O: Impact of SGLT2 inhibitors on metabolic status in patients with psychiatric disorders undergoing treatment with second-generation antipsychotics (Review). Exp Ther Med. 25(125)2023.PubMed/NCBI View Article : Google Scholar
20	Fitzgerald I, O'Connell J, Keating D, Hynes C, McWilliams S and Crowley EK: Metformin in the management of antipsychotic-induced weight gain in adults with psychosis: Development of the first evidence-based guideline using GRADE methodology. Evid Based Ment Health. 25:15–22. 2022.PubMed/NCBI View Article : Google Scholar
21	Hiluy JC, Nazar BP, Gonçalves WS, Coutinho W and Appolinario JC: Effectiveness of pharmacologic interventions in the management of weight gain in patients with severe mental illness: A systematic review and meta-analysis. Prim Care Companion CNS Disord. 21(19r02483)2019.PubMed/NCBI View Article : Google Scholar
22	Medak KD, Shamshoum H, Peppler WT and Wright D: GLP1 receptor agonism protects against acute olanzapine-induced hyperglycemia. Am J Physiol Endocrinol Metab. 319:E1101–E1111. 2020.PubMed/NCBI View Article : Google Scholar
23	Boyda HN, Tse L, Procyshyn RM, Wong D, Wu TH, Pang CC and Barr AM: A parametric study of the acute effects of antipsychotic drugs on glucose sensitivity in an animal model. Prog Neuropsychopharmacol Biol Psychiatry. 34:945–954. 2010.PubMed/NCBI View Article : Google Scholar
24	Chintoh AF, Mann SW, Lam L, Lam C, Cohn TA, Fletcher PJ, Nobrega JN, Giacca A and Remington G: Insulin resistance and decreased glucose-stimulated insulin secretion after acute olanzapine administration. J Clin Psychopharmacol. 28:494–499. 2008.PubMed/NCBI View Article : Google Scholar
25	Mayfield K, Siskind D, Winckel K, Russell AW, Kisely S, Smith G and Hollingworth S: Glucagon-like peptide-1 agonists combating clozapine-associated obesity and diabetes. J Psychopharmacol. 30:227–236. 2016.PubMed/NCBI View Article : Google Scholar
26	Deutch AY: Liraglutide for the treatment of antipsychotic drug-induced weight gain. JAMA Psychiatry. 74:1172–1173. 2017.PubMed/NCBI View Article : Google Scholar
27	Heppner KM, Kirigiti M, Secher A, Paulsen SJ, Buckingham R, Pyke C, Knudsen LB, Vrang N and Grove KL: Expression and distribution of glucagon-like peptide-1 receptor mRNA, protein and binding in the male nonhuman primate (Macaca mulatta) brain. Endocrinolog. 156:255–267. 2015.PubMed/NCBI View Article : Google Scholar
28	Zhong P, Zeng H, Huang M, Fu W and Chen Z: Efficacy and safety of once-weekly semaglutide in adults with overweight or obesity: A meta-analysis. Endocrine. 75:718–724. 2022.PubMed/NCBI View Article : Google Scholar
29	Avgerinos I, Michailidis T, Liakos A, Karagiannis T, Matthews DR, Tsapas A and Bekiari E: Oral semaglutide for type 2 diabetes: A systematic review and meta-analysis. Diabetes Obes Metab. 22:335–345. 2020.PubMed/NCBI View Article : Google Scholar
30	Blair HA and Keating GM: Albiglutide: A review of its use in patients with type 2 diabetes mellitus. Drugs. 75:651–663. 2015.PubMed/NCBI View Article : Google Scholar
31	Chudleigh RA, Platts J and Bain SC: Comparative effectiveness of long-acting GLP-1 receptor agonists in type-2 diabetes: A short review on the emerging data. Diabetes Metab Syndr Obes. 13:433–438. 2020.PubMed/NCBI View Article : Google Scholar
32	Umpierrez G, Tofé Povedano S, Pérez Manghi F, Shurzinske L and Pechtner V: Efficacy and safety of dulaglutide monotherapy versus metformin in type 2 diabetes in a randomized controlled trial (AWARD-3). Diabetes Care. 37:2168–2176. 2014.PubMed/NCBI View Article : Google Scholar
33	Madsbad S: Review of head-to-head comparison of glucagon-like peptide-1 receptor agonists. Diabetes Obes Metab. 18:317–332. 2016.PubMed/NCBI View Article : Google Scholar
34	Roca-Rodriguez MM, Muros de Fuentes MT, Piédrola-Maroto G, Quesada-Charneco M, Maraver-Selfa S, Tinahones FJ and Mancha-Doblas I: Lixisenatide in patients with type 2 diabetes and obesity: Beyond glycamic control. Aten Primaria. 49:294–299. 2017.PubMed/NCBI View Article : Google Scholar : (In Spanish).
35	Rosenstock J, Raccah D, Korányi L, Maffei L, Boka G, Miossec P and Gerich JE: Efficacy and safety of lixisenatide once daily versus exenatide twice daily in type 2 diabetes inadequately controlled on metformin: A 24-week, randomized, open-label, active-controlled study (GetGoal-X). Diabetes Care. 36:2945–2951. 2013.PubMed/NCBI View Article : Google Scholar
36	Kapitza C, Forst T, Coester HV, Poitiers F, Ruus P and Hincelin-Méry A: Pharmacodynamic characteristics of lixisenatide once daily versus liraglutide once daily in patients with type 2 diabetes insufficiently controlled on metformin. Diabetes Obes Metab. 15:642–649. 2013.PubMed/NCBI View Article : Google Scholar
37	Ishøy PL, Fagerlund B, Broberg BV, Bak N, Knop FJ, Glenthøj BY and Ebdrup BH: No cognitive-enhancing effect of GLP-1 receptor agonism in antipsychotic-treated, obese patients with schizophrenia. Acta Psychiatr Scand. 136:52–62. 2017.PubMed/NCBI View Article : Google Scholar
38	Siskind DJ, Russell AW, Gamble C, Winckel K, Mayfield K, Hollingworth S, Hickman I, Siskind V and Kisely S: Treatment of clozapine-associated obesity and diabetes with exenatide in adults with schizophrenia: A randomized controlled trial (CODEX). Diabetes Obes Metab. 20:1050–1055. 2018.PubMed/NCBI View Article : Google Scholar
39	Htike ZZ, Zaccardi F, Papamargaritis D, Webb DR, Khunti K and Davies MJ: Efficacy and safety of glucagon-like peptide-1 receptor agonists in type 2 diabetes: A systematic review and mixed-treatment comparison analysis. Diabetes Obes Metab. 19:524–536. 2017.PubMed/NCBI View Article : Google Scholar
40	Min T and Bain SC: The role of tirzepatide, dual GIP and GLP-1 receptor agonist, in the management of type 2 diabetes: The SURPASS clinical trials. Diabetes Ther. 12:143–157. 2021.PubMed/NCBI View Article : Google Scholar
41	Ludvik B, Giorgino F, Jódar E, Frias JP, Fernández Landó L, Brown K, Bray R and Rodríguez Á: Once-weekly tirzepatide versus once-daily insulin degludec as add-on to metformin with or without SGLT2 inhibitors in patients with type 2 diabetes (SURPASS-3): A randomized, open-label, parallel-group, phase 3 trial. Lancet. 398:583–598. 2021.PubMed/NCBI View Article : Google Scholar
42	Brozek JL, Akl EA, Compalati E, Kreis J, Terraciano L, Fiocchi A, Ueffing E, Andrews J, Alonso-Coello P, Meerpohl JJ, et al: Grading quality of evidence and strength of recommendations in clinical practice guidelines part 3 of 3. The GRADE approach to developing recommendations. Allergy. 66:588–595. 2011.PubMed/NCBI View Article : Google Scholar
43	Neumann I, Santesso N, Akl EA, Rind DM, Vandvik PO, Alonso-Coello P, Agoritsas T, Mustafa RA, Alexander PE, Schünemann H and Guyatt GH: A guide for health professionals to interpret and use recommendations in guidelines developed with the GRADE approach. J Clin Epidemiol. 72:45–55. 2016.PubMed/NCBI View Article : Google Scholar
44	Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, Shamseer L, Tetzlaff JM, Akl EA, Brennan SE, et al: The PRISMA 2020 statement: An updated guideline for reporting systematic reviews. BMJ. 372(n71)2021.PubMed/NCBI View Article : Google Scholar
45	Cooke A, Smith D and Booth A: Beyond PICO: The SPIDER tool for qualitative evidence synthesis. Qual Health Res. 22:1435–1443. 2012.PubMed/NCBI View Article : Google Scholar
46	Schünemann H, Brożek J, Guyatt G and Oxman A (eds): GRADE handbook for grading quality of evidence and strength of recommendations. Updated October 2013. The GRADE Working Group, 2013. guidelinedevelopment.org/handbook. Accessed January 7, 2023.
47	Babic I, Gorak A, Engel M, Sellers D, Else P, Osborne AL, Pai N, Huang XF, Nealon J and Weston-Green K: Liraglutide prevents metabolic side-effects and improves recognition and working memory during antipsychotic treatment in rats. J Psychopharmacol. 32:578–590. 2018.PubMed/NCBI View Article : Google Scholar
48	Lykkegaard K, Larsen PJ, Vrang N, Bock C, Bock T and Knudsen LB: The once-daily human GLP-1 analog, liraglutide, reduces olanzapine-induced weight gain and glucose intolerance. Schizophr Res. 103:94–103. 2008.PubMed/NCBI View Article : Google Scholar
49	Ishøy PL, Knop FK, Vilsbøll T, Glenthøj BY and Ebdrup BH: Sustained weight loss after treatment with a glucagon-like peptide-1 receptor agonist in an obese patient with schizophrenia and type 2 diabetes. Am J Psychiatry. 170:681–682. 2013.PubMed/NCBI View Article : Google Scholar
50	Siskind D, Wysoczanski D, Russell A and Ashford M: Weight loss associated with exenatide in an obese man with diabetes commenced on clozapine. Aust N Z J Psychiatry. 50:702–703. 2016.PubMed/NCBI View Article : Google Scholar
51	Larsen JR, Vedtofte L, Jakobsen MSL, Jespersen HR, Jakobsen MI, Svensson CK, Koyuncu K, Schjerning O, Oturai PS, Kjaer A, et al: Effect of liraglutide treatment on prediabetes and overweight or obesity in clozapine- or olanzapine-treated patients with schizophrenia spectrum disorder: A randomized clinical trial. JAMA Psychiatry. 74:719–728. 2017.PubMed/NCBI View Article : Google Scholar
52	Svensson CK, Larsen JR, Vedtofte L, Jakobsen MSL, Jespersen HR, Jakobsen MI, Koyuncu K, Schjerning O, Nielsen J, Ekstrøm CT, et al: One-year follow-up on liraglutide treatment for prediabetes and overweight/obesity in clozapine- or olanzapine-treated patients. Acta Psychiatr Scand. 139:26–36. 2019.PubMed/NCBI View Article : Google Scholar
53	Siskind D, Russell A and Kisely S: T44. 12-Month follow-up of metabolic measures following a randomised controlled trial of treatment of clozapine associated obesity and diabetes with exenatide (CODEX). Schizophr Bull. 46 (Suppl.1)(S248)2020.PubMed/NCBI View Article : Google Scholar
54	Ishøy PL, Knop FK, Broberg BV, Bak N, Andersen UB, Jørgensen NR, Holst JJ, Glenthøj BY and Ebdrup BH: Effect of GLP-1 receptor agonist treatment on body weight in obese antipsychotic-treated patients with schizophrenia: A randomized, placebo-controlled trial. Diabetes Obes Metab. 19:162–171. 2017.PubMed/NCBI View Article : Google Scholar
55	U.S. National Library of Medicine: Exenatide for the treatment of weight gain associated with olanzapine in obese adults. NCT00845507. https://clinicaltrials.gov/ct2/show/results/NCT00845507. Accessed June 10, 2022.
56	Whicher CA, Price HC, Phiri P, Rathod S, Barnard-Kelly K, Ngianga K, Thorne K, Asher C, Peveler RC, McCarthy J and Holt RIG: The use of liraglutide 3.0 mg daily in the management of overweight and obesity in people with schizophrenia, schizoaffective disorder and first episode psychosis: Results of a pilot randomized, double-blind, placebo-controlled trial. Diabetes Obes Metab. 23:1262–1271. 2021.PubMed/NCBI View Article : Google Scholar
57	Perlis LT, Lamberti JS and Miedlich SU: Glucagon-like peptide analogs are superior for diabetes and weight control in patients on antipsychotic medications: A retrospective cohort study. Prim Care Companion CNS Disord. 22(19m02504)2020.PubMed/NCBI View Article : Google Scholar
58	Lee SE, Lee NY, Kim SH, Kim KA and Kim YS: Effect of liraglutide 3.0 mg treatment on weight reduction in obese antipsychotic-treated patients. Psychiatry Res. 299(113830)2021.PubMed/NCBI View Article : Google Scholar
59	Siskind D, Hahn M, Correll CU, Fink-Jensen A, Russell AW, Bak N, Broberg BV, Larsen J, Ishøy PL, Vilsbøll T, et al: Glucagon-like peptide-1 receptor agonists for antipsychotic-associated cardio-metabolic risk factors: A systematic review and individual participant data meta-analysis. Diabetes Obes Metab. 21:293–302. 2019.PubMed/NCBI View Article : Google Scholar
60	Wang Y, Wang D, Cheng J, Fang X, Chen Y, Yu L, Ren J, Tian Y and Zhang C: Efficacy and tolerability of pharmacological interventions on metabolic disturbances induced by atypical antipsychotics in adults: A systematic review and network meta-analysis. J Psychopharmacol. 35:1111–1119. 2021.PubMed/NCBI View Article : Google Scholar
61	Cooper SJ and Reynolds GP: With expert co-authors (in alphabetical order). Barnes T, England E, Haddad PM, Heald A, Holt R, Lingford-Hughes A, Osborn D, et al: BAP guidelines on the management of weight gain, metabolic disturbances and cardiovascular risk associated with psychosis and antipsychotic drug treatment. J Psychopharmacol. 30:717–748. 2016.PubMed/NCBI View Article : Google Scholar
62	U.S. National Library of Medicine. Semaglutide in comorbid schizophrenia spectrum disorder and obesity (Sema). NCT05333003. Retrieved online at https://clinicaltrials.gov/ct2/show/NCT05333003 (accessed June 10, 2022).
63	Sailer CO, Sulieman I, Macedo CT, Parodi MR, Machuca M, Sanchez CJS, Murrieta CGI, Delgoshaie N, Nanbu DY, Sarmento R, et al: The glucagon like peptide-1 analogue dulaglutide to prevent antipsychotic induced weight gain-a study protocol proposal. Prin Pract Clin Res. 5:19–26. 2019.
64	Queensland Centre for Mental Health Research: Cadence-CoaST clinical trial. https://qcmhr.org/research/studies-recruiting-participants/2759-2/. Accessed June 10, 2022.
65	Shetty R, Basheer FT, poojari PG, Thunga G, Chandran VP and Acharya LD: Adverse drug reactions of GLP-1 agonists: A systematic review of case reports. Diabetes Metab Syndr. 16(102427)2022.PubMed/NCBI View Article : Google Scholar